Can a drug combo outsmart a tough breast cancer subtype?
NCT ID NCT07760844
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This phase III trial is testing whether adding everolimus to trastuzumab rezetecan helps people with a specific subtype of triple-negative breast cancer (called luminal androgen receptor) live longer without their disease progressing. The study enrolls adults with advanced or metastatic cancer that has not responded well to prior treatments. Participants receive either the antibody-drug conjugate alone or in combination with everolimus, and researchers compare how long the cancer stays controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab rezetecan (an antibody-drug conjugate targeting HER2) with or without everolimus
- What this could lead to
- If adding everolimus improves progression-free survival, this could become a new standard treatment for this hard-to-treat breast cancer subtype.
- What could go wrong
- This is an early-phase trial with a relatively small number of participants, and the combination may not prove more effective than the single drug. Side effects from the combination could also limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?